On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q4 2023 earnings per share (EPS) of $20.45, up 536.03% year over year. Total Spyre Therapeutics earnings for the quarter were -$63.18 million. In the same quarter last year, Spyre Therapeutics's earnings per share (EPS) was -$4.69.
As of Q1 2024, Spyre Therapeutics's earnings has grown year over year. Spyre Therapeutics's earnings in the past year totalled -$338.79 million.
What is SYRE's earnings date?
Spyre Therapeutics's earnings date is Invalid Date. Add SYRE to your watchlist to be reminded of SYRE's next earnings announcement.
What was SYRE's revenue last quarter?
On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Spyre Therapeutics's revenue was $168.00 thousand.
What was SYRE's revenue growth in the past year?
As of Q1 2024, Spyre Therapeutics's revenue has grown -61.96% year over year. This is 231.26 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Spyre Therapeutics's revenue in the past year totalled $886.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.